Samsung Bioepis emphasized the role of a similar

Expecting financial savings

Emphasis on customized strategies for each country to expand the role of biosimilars

As financial savings and patient benefits, such as health insurance, are emerging as major issues both domestically and globally, biosimilars that have the same effect as the original and are cheaper are expanding their presence.

 

It is the expert's view that the effects are felt even when looking at overseas cases where active prescriptions are already being made.

 

Samsung Bioepis held a satellite symposium at the 15th World Lupus Academic Conference, the 43rd Korean Society of Rheumatology Spring Conference, and the 17th LUPUS & KCR 2023 organized by the Korean Lupus Research Association and the Korean Society of Rheumatology, which were held at COEX on the 18th.

 

The role of biosimilars was discussed.

 

This symposium is the first academic discussion held by Samsung Bioepis at a domestic academic conference, and it delivered information on the current status and economic effectiveness of biosimilars in the field of autoimmune disease treatment to domestic and foreign rheumatology specialists.

 

Biosimilars for 21 original biopharmaceuticals have been developed worldwide.

 

Looking at the number of products approved for biosimilar sales by country, 78 in the EU, 40 in the US, 51 in Canada, 51 in Australia, 33 in Japan, and 20 in Korea.

 

Speakers who participated in the Samsung Bioepis Symposium on this day emphasized that the use of biosimilars can lead to economic effects on the healthcare system.

 

Dr.

 

Aslam H.

 

Anis, from the Graduate School of Population Health at the University of British Columbia in Canada, mentioned the need for an institutional mechanism for biosimilars to settle down under the theme of 'Economics of Anti-TNF Biosimilars'.

 

Dr.

 

Anis said, “Biosimilars trigger market competition, which promotes economic benefits, such as improving education for medical staff, developing new formulations, and conducting administrative procedures.” is estimated at about 30 billion euros." As an example, three anti-TNFs were selected: Infliximab, Etanercept, and Adalimumab biosimilar market penetration rates were analyzed with IQVIA data.

 

Considering these points, it is a view that countries that are concerned about financial savings, such as health insurance, are considering expanding the role of biosimilars, and related markets will continue to grow.

 

From this point of view, Dr.

 

Anis believes that it is necessary to respond in line with each country's drug price policy, such as the conversion of prescriptions to biosimilars for previously treated patients, policies to maintain the price advantage of biosimilars, and periodic price re-evaluation.

 

Dr.

 

Anis said, “It is necessary to realize that the use of biosimilars brings economic benefits to the healthcare system.” Professor Jonathan Kay of the University of Massachusetts School of Medicine, who gave a presentation titled 'What rheumatologists should know about biosimilars before prescribing', mentioned that biosimilars can reduce treatment costs and offer various alternatives.

 

In particular, he argues that there should be no prejudice in prescription as biosimilars are drugs that have undergone rigorous comparative analysis and clinical trial evaluation with expired patent drugs and have been approved by regulatory agencies.

 

Professor Kay said, "FDA-approved biosimilars have equivalent efficacy and similar safety through extensive comparative analysis with the originals." It has potential social benefits.” He also explained, "Using inexpensive biosimilars can provide more people with an opportunity for effective drug treatment." "The cost savings from using biosimilars can be reinvested in research and development to develop new therapies that address unmet drug demand," he added.